Pediatric fever of uncertain source
From Tintinalli
Management of patients who are well-appearing, vaccinated, and no clinical source of fever
Age Group | Evaluation | Treatment |
0-28d, ≥38C SBI incidence of ill appearing: 13%–21% if not ill appearing: <5% |
CBC, blood Cx UA, Ucx CSF cell count, GS, Cx CXR (only if resp sx) Stool testing (if diarrhea present) |
Admit Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) |
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)
if not ill appearing: <5%
|
Same as for neonates |
Discharge if: 1. WBC <15K but >5K and <20% bands 2. UA negative Admit and perform LP if above are not met Treat with CTX 50mg/kg (if CSF normal), 100mg/kg (if signs of meningitis) |
57d-6mo, ≥38 Non-UTI SBI incidence is estimated to be negligible UTI is 3%–8%
|
UA and Ucx alone OR treat 57-90d using Philadelphia Protocol |
Discharge if negative Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient Admit and tx with CTX if fail criteria for d/c |
57d-6mo, ≥39 (102.2) SBI incidence is estimated <1%; non-UTI SBI incidence is estimated to be negligible. UTI is 3%–8% |
UA and Ucx alone OR UA and Ucx + CBC + blood cx |
Discharge if negative Treat for UTI as above If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr If WBC>20K consider CXR and CSF |
6–36 mo Non-UTI SBI incidence is <0.4% UTI in girls ≤8% UTI in boys (<12 mo) ≤ 2% Uncircumcised boys (1–2 y) remains 2% |
UA and Ucx in: (girls 6-24mo) (circ 6-12mo) (uncirc 6-24mo) |
Discharge if negative Treat for UTI as above as outpatient |
>36mo | No further w/u is routinely necessary |
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d
Harbor-UCLA Protocol
0-28dy
Child Appearance | Work Up | Treatment | Disposition | Follow Up |
T>=38
Toxic or Well |
|
|
Admit | N/A |
28dy-90dy
Appearance | Work Up | Treatment | Disposition | Follow Up |
T>=38 + Toxic | Admit | |||
T>=38 + Well (Option 1) |
Outpatient^^^ | IfW/U negative, meets outpt | ||
T>=38 + Toxic (Option 2) |
Outpatient^^^ |
Age Group | Evaluation | Treatment |
T>=38 + Toxic |
|
Discharge if:
Admit if:
|
T>=38 + Well |
|
Discharge if:
Admit if:
|
57d-6mo, ≥38 Non-UTI SBI incidence is estimated to be negligible |
UA and Ucx alone OR treat 57-90d using Philadelphia Protocol |
Discharge if negative Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient Admit and tx with CTX if fail criteria for d/c |
57d-6mo, ≥39 (102.2) SBI incidence is estimated <1%; non-UTI SBI incidence is estimated to be negligible. UTI is 3%–8% |
UA and Ucx alone OR UA and Ucx + CBC + blood cx |
Discharge if negative Treat for UTI as above If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr If WBC>20K consider CXR and CSF |
90dy-36mo
Age Group | Evaluation | Treatment |
57d-6mo, ≥39 (102.2) SBI incidence is estimated <1%; non-UTI SBI incidence is estimated to be negligible. UTI is 3%–8% |
UA and Ucx alone OR UA and Ucx + CBC + blood cx |
Discharge if negative Treat for UTI as above If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr If WBC>20K consider CXR and CSF |
6–36 mo Non-UTI SBI incidence is <0.4% UTI in girls ≤8% UTI in boys (<12 mo) ≤ 2% Uncircumcised boys (1–2 y) remains 2% |
UA and Ucx in: (girls 6-24mo) (circ 6-12mo) (uncirc 6-24mo) |
Discharge if negative Treat for UTI as above as outpatient |
>36mo | No further w/u is routinely necessary |
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d
^Can use ceftriaxone 50-100 mg/kg, but concern for bilirubin displacement ^^Add acyclovir if HSV infection in baby or mother, CSF pleocytoisis, concerning skin lesions, seizures, abnl LFTs
See Also
Source
Tintinalli